Comparative analysis of quality of life in patients treated with canagliflozine or DPP-IV inhibitor

por Nina A. Petunina, Anna L. Terekhova, Ekaterina V. Goncharova
Publicado 2016

Canagliflozin review – safety and efficacy profile in patients with T2DM

por Jakher H, Chang TI, Tan M, Mahaffey KW
Publicado 2019

Empagliflozin in type 1 diabetes

por Mathieu C, Van Den Mooter L, Eeckhout B
Publicado 2019

Intensification of glucose-lowering treatment in patients with diabetes mellitus type 2 on insulin therapy: Perspectives of dapagliflozin

por Olga Yuryevna Sukhareva, Marina Vladimirovna Shestakova
Publicado 2016

Emerging use of combination therapies for the management of type 2 diabetes – focus on saxagliptin and dapagliflozin

por Yu H, Woo VC
Publicado 2017

Glycemia control and glucose-lowering therapy in patients with type 2 diabetes mellitus and cardiovascular disease (review of multicenter randomized trials)

por Sergey V. Kakorin, Ruben A. Iskandaryan, Ashot M. Mkrtumyan
Publicado 2016

Efficacy and safety of canagliflozin in type 2 diabetes mellitus patients with biopsy-proven nonalcoholic steatohepatitis classified as stage 1–3 fibrosis

por Seko Y, Nishikawa T, Umemura A, Yamaguchi K, Moriguchi M, Yasui K, Kimura M, Iijima H, Hashimoto T, Sumida Y, Okanoue T, Itoh Y
Publicado 2018

A Clinical Study on the Association of Sodium-Glucose Cotransporter 2 Inhibitors and Acute Kidney Injury Among Diabetic Chinese Population

por Shen L, Yang H, Fang X, Huang H, Yao W, Chen D, Shen Y
Publicado 2021

Patient considerations in type 2 diabetes – role of combination dapagliflozin–metformin XR

por Kuecker CM, Vivian EM
Publicado 2016

Empagliflozin Ameliorates Free Fatty Acid Induced-Lipotoxicity in Renal Proximal Tubular Cells via the PPARγ/CD36 Pathway in Obese Mice

por Chiang-Chi Huang, Chia-An Chou, Wei-Yu Chen, Jenq-Lin Yang, Wen-Chin Lee, Jin-Bor Chen, Chien-Te Lee, Lung-Chih Li
Publicado 2021